subscribeSubscribe
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline
PR NEWSWIRE
27 Apr 2023
Share Share
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML
BUSINESSWIRE
20 Apr 2023
Share Share
Jazz Pharma Secures Eight Additional Provincial Reimbursements for Vyxeos

Jazz Pharma Secures Eight Additional Provincial Reimbursements for Vyxeos
PRESS RELEASE
08 Mar 2023
Share Share
Teva`s troubled plant seen to create injectable drug shortages

Teva`s troubled plant seen to create injectable drug shortages
Joseph Keenan FIERCEPHARMA
24 May 2022
Share Share
BDR launches India’s first generic Midostaurin (MSTARIN) to treat Leukemia

BDR launches India’s first generic Midostaurin (MSTARIN) to treat Leukemia
EXPRESS PHARMA
07 Dec 2021
Share Share
Jazz Announces FDA Approval of Additional Indication for Vyxeos®

Jazz Announces FDA Approval of Additional Indication for Vyxeos®
PRNEWSWIRE
30 Mar 2021
Share Share
Final NICE green light for Pfizer’s Mylotarg

Final NICE green light for Pfizer’s Mylotarg
Selina McKee PHARMA TIMES
15 Nov 2018
Share Share
NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML

NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML
PHARMACEUTICAL TECH
10 Nov 2018
Share Share
NICE recommends Vyxeos for specific secondary AML

NICE recommends Vyxeos for specific secondary AML
BIOSPECTRUM
08 Nov 2018
Share Share
Vyxeos® Receives Marketing Authorisation in the European Union for AML

Vyxeos® Receives Marketing Authorisation in the European Union for AML
PR NEWSWIRE
27 Aug 2018
Share Share